Lexaria Bioscience, a Kelowna, Canada-based company that develops drug delivery platforms, is seeking a listing on the Nasdaq. The company is currently listed on the Over-the-Counter Markets under the ticker "LXRP," as well as the Canadian Securities Exchange under the ticker symbol "LXX."
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.20 |
|---|---|
| 52-week range | $1.20 - $6.85 |
| 50-day moving average | $2.89 |
| 200-day moving average | $3.02 |
| Wall St. target price | $10.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.41 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.17 from 2024-11-19
| 1 week (2024-11-14) | 2.36% |
|---|---|
| 1 month (2024-10-21) | -21.09% |
| 3 months (2024-08-21) | -34.04% |
| 6 months (2024-05-21) | -27.42% |
| 1 year (2023-11-21) | 72.22% |
|---|---|
| 2 years (2022-11-21) | -2.25% |
| 3 years (2021-11-19) | 5.57 |
| 5 years (2019-11-21) | 13.5 |
| Revenue TTM | $411,019 |
|---|---|
| Gross profit TTM | $183,556 |
| Return on assets TTM | -38.21% |
| Return on equity TTM | -70.66% |
| Profit margin | 0% |
| Book value | $0.64 |
| Market Capitalization | $37 million |
TTM: trailing 12 months
We're not expecting Lexaria Bioscience Corp to pay a dividend over the next 12 months.
You may also wish to consider:
Lexaria Bioscience Corp's shares were split on a 1:30 basis on 11 January 2021 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lexaria Bioscience Corp shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Lexaria Bioscience Corp shares which in turn could have impacted Lexaria Bioscience Corp's share price.
Over the last 12 months, Lexaria Bioscience Corp's shares have ranged in value from as little as $1.2 up to $6.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexaria Bioscience Corp's is 1.056. This would suggest that Lexaria Bioscience Corp's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Lexaria Bioscience Corp's beta into context you can compare it against those of similar companies.
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.